On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
Certara2026年2月26日
Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach
Explore how a collaborative “sandbox” approach—combining flexible regulation, data modeling, and stakeholder engagement—can transform rare…
Certara2026年1月30日
Certara’s Virtual Twin® QSP Models: Transforming Rare Disease Research into Clinical Insights
Certara’s Virtual Twin® QSP Models are transforming rare disease drug development, with real-world insights from…
Certara2025年11月25日
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema
Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…
Certara2025年11月12日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025年11月10日
Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research
The article, "Move Away From Animal-Only Testing May Improve, Speed Rare Disease Research," explores a…
Danielle Pillsbury2025年9月10日
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
Certara2025年7月29日
Digital twins and virtual trials: A new era in rare disease drug development
Discover how using digital twins in rare disease drug development is improving precision and accelerating…
Certara2025年7月22日
Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe
Lorem ipsum dolor sit amet consectetur. At venenatis urna sapien ut lorem enim. Morbi lectus…
Certara2025年2月28日
Accelerating CMC Success in Rare Disease Drug Development
New drug approvals in rare diseases are rising, bringing hope to patients. But with accelerated…
Certara2025年2月26日
